Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia.
作者信息
Kim Tae Kon, Xu Mina L, Podoltsev Nikolai A, Prebet Thomas, Barbarotta Lisa, Amin Kejal, Kasberg Stephanie, Roche Kristen, Stahl Maximilian, Gore Steven D, Zeidan Amer M
机构信息
Section of Hematology/Department of Internal Medicine and Yale Cancer Center, Yale University School of Medicine, Smilow Cancer Hospital at Yale-New Haven, New Haven, USA.
Department of Pathology, Yale School of Medicine, New Haven, USA.
出版信息
Ann Hematol. 2016 Oct;95(11):1895-8. doi: 10.1007/s00277-016-2761-4. Epub 2016 Jul 29.
Abstract
摘要
相似文献
1
Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia.
Ann Hematol. 2016 Oct;95(11):1895-8. doi: 10.1007/s00277-016-2761-4. Epub 2016 Jul 29.
2
Successful treatment of acute lymphoblastic leukemia in a child with cystic fibrosis.
Med Pediatr Oncol. 1994;22(6):414-6. doi: 10.1002/mpo.2950220612.
3
Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
Haematologica. 2012 Jul;97(7):1048-56. doi: 10.3324/haematol.2011.047613. Epub 2012 Jan 22.
4
True histiocytic lymphoma following therapy for lymphoblastic neoplasms.
Blood. 1996 Jun 15;87(12):5207-12.
5
Histiocytic sarcoma: secondary neoplasm or "transdifferentiation" in the setting of B-acute lymphoblastic leukemia.
Blood. 2016 Nov 17;128(20):2475. doi: 10.1182/blood-2016-08-735795.
6
Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia.
Am J Hematol. 2009 Dec;84(12):849-50. doi: 10.1002/ajh.21548.
7
Long-term results of AIEOP-8805 protocol for acute B-cell lymphoblastic leukemia of childhood.
Pediatr Blood Cancer. 2011 Apr;56(4):544-50. doi: 10.1002/pbc.22787. Epub 2010 Dec 15.
8
Methotrexate polyglutamation may lack prognostic significance in children with B-cell precursor acute lymphoblastic leukemia treated with intensive oral methotrexate.
J Pediatr Hematol Oncol. 2002 Nov;24(8):636-42. doi: 10.1097/00043426-200211000-00007.
9
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
Haematologica. 2014 Jul;99(7):1212-9. doi: 10.3324/haematol.2013.100073. Epub 2014 Apr 11.
10
Unexpected pancytopenia following treatment of acute lymphoblastic leukemia.
Am J Hematol. 2012 Apr;87(4):412. doi: 10.1002/ajh.22159. Epub 2011 Sep 26.
本文引用的文献
1
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Lancet Oncol. 2015 Jan;16(1):57-66. doi: 10.1016/S1470-2045(14)71170-2. Epub 2014 Dec 16.
2
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
J Clin Oncol. 2014 Dec 20;32(36):4134-40. doi: 10.1200/JCO.2014.56.3247. Epub 2014 Nov 10.
3
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
N Engl J Med. 2013 Apr 18;368(16):1509-1518. doi: 10.1056/NEJMoa1215134. Epub 2013 Mar 25.
4
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.
J Clin Oncol. 2013 Feb 20;31(6):676-83. doi: 10.1200/JCO.2012.46.2309. Epub 2012 Nov 19.
5
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
Blood. 2012 Jun 28;119(26):6226-33. doi: 10.1182/blood-2012-01-400515. Epub 2012 May 16.
6
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16.
7
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.
Science. 2008 Aug 15;321(5891):974-7. doi: 10.1126/science.1158545.
Zotero 插件